investor briefing

Teleconference/Webcast: Investor Briefing – Licensing and development
agreement with European partner, Hospira
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (December 14, 2009) –
ChemGenex Pharmaceuticals Limited (ChemGenex) (ASX:CXS) will host an investor briefing
teleconference tomorrow, Tuesday 15th December at 11:00am Australian Eastern Daylight Savings
Time (Monday 10th December 4:00pm U.S. Pacific Time).
ChemGenex CEO Dr. Greg Collier will update investors on the development and commercialization
agreement that ChemGenex has signed with Hospira Inc. for the commercialization of omacetaxine in
Europe, the Middle East and parts of Africa.
If you would like to attend the call we request that you register your interest with Kyahn
Williamson of Buchan Consulting – [email protected] or telephone 03 9866 4722.
Teleconference details:
Domestic access (toll free) details are below:
Access Number: 02 8212 8410
Toll Free Number: 1800 153 721
Participant Pin Code: 189117#
International access (toll free) details are below:
0800 442 709 New Zealand
800 616 2259 Singapore
800 933 733 Hong Kong
001 803 011 3830 Indonesia
0034 800 400746 Japan
1866 307 0659 USA/Canada
0808 2389 067 UK
0800 000 3882 Germany
0805 100 294 France
0800 000 601 Switzerland
If you would like to dial-in from other locations please contact Kyahn Williamson.
About